PaxMedica is a biotechnology business based in the US. PaxMedica shares (PXMD) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior. PaxMedica employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $0.00 - $0.85 |
| 50-day moving average | $0.00 |
| 200-day moving average | $0.09 |
| Wall St. target price | $3.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.77 |
Historical closes compared with the close of $0.0001 from 2025-04-22
| 1 week (2025-04-17) | 0.0001 |
|---|---|
| 1 month (2025-03-25) | -50.00% |
| 3 months (2025-01-24) | -99.68% |
| 6 months (2024-10-25) | -99.90% |
| 1 year (2024-04-24) | -99.99% |
|---|---|
| 2 years (2023-04-24) | -100.00% |
| 3 years (2022-04-21) | N/A |
| 5 years (2020-04-21) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -324.69% |
| Return on equity TTM | -7716.49% |
| Profit margin | 0% |
| Book value | $-0.23 |
| Market Capitalization | $12,563 |
TTM: trailing 12 months
We're not expecting PaxMedica to pay a dividend over the next 12 months.
PaxMedica's shares were split on a 1:17 basis on 30 October 2023 . So if you had owned 17 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your PaxMedica shares – just the quantity. However, indirectly, the new 1600% higher share price could have impacted the market appetite for PaxMedica shares which in turn could have impacted PaxMedica's share price.
Over the last 12 months, PaxMedica's shares have ranged in value from as little as $0.0001 up to $0.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while PaxMedica's is -46.291. This would suggest that PaxMedica's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, PaxMedica has bucked the trend.
PaxMedica, Inc. , a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.